HOME > TOP STORIES

TOP STORIES

BUSINESS Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review

April 26, 2024
REGULATORY Japan Plans More Prompt Drug Approvals from 2025, Within 3 Weeks of Panel Nod

April 25, 2024
BUSINESS Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief

April 25, 2024
BUSINESS Bayer Poised to Navigate Patent Cliff with Blockbuster Hopefuls for Stroke, Kidney Disease

April 24, 2024
REGULATORY Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule

April 23, 2024
REGULATORY MHLW Proposes Simplified Generic Delisting Scheme

April 22, 2024
REGULATORY More Unexpected Substances in Kobayashi’s Beni-Koji Supplements: MHLW

April 22, 2024
REGULATORY MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda

April 19, 2024
ORGANIZATION Doctors’ Lobby Objects MOF Proposal for CEA Use in Reimbursement Decisions

April 18, 2024
REGULATORY MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions

April 17, 2024
BUSINESS Moderna to File mRNA RSV Vaccine in Japan within 2024: Exec

April 17, 2024
REGULATORY PMDA Stepping Up Generic Compliance Inspections from August Approvals

April 16, 2024
BUSINESS 80%-Plus Doctors Seek In-Person Meetings with Reps: Lilly Survey

April 16, 2024
REGULATORY Japan Might Approve 1st Eylea Biosimilar by June, but Not AMD Use

April 15, 2024
BUSINESS Wholesaler Purchase Prices of Unprofitable Drugs on Upward Trend after FY2024 Revision

April 12, 2024
BUSINESS Moderna Plots Successive Launches in Japan, Updated COVID Jab by Fall: Medical Chief

April 11, 2024
REGULATORY Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed

April 11, 2024
REGULATORY Lagevrio to Get 8.2% Price Cut in July, 2.7% for Kerendia: CEA

April 11, 2024
REGULATORY LDP Healthcare Clique Urges Rethink of Rationale for Off-Year Drug Price Revisions

April 10, 2024
BUSINESS R&D Jobs Make Up 40% of Pharma New Grads Hires This Spring, Sales Reps Only 20%: Poll

April 9, 2024

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…